Let’s Talk About Hims & Hers
This wasn’t a great week for our telehealth pioneer Hims & Hers Health (HIMS). Wall Street didn’t love the earnings release Monday night, and as I write this, the shares are down about 18% from Monday’s close. Of course, we’re used to a little volatility in this stock. HIMS moves… a lot. That’s to be expected for a disruptive innovator, and it’s the “price” we pay for a stock legitimately capable of delivering a 10X return.
Read More